Clinical trial
A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
NCT02951195 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- January 31, 2018
- Enrollment
- 80 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.